Search bioRxiv⌕ Search

Biology subjects

Baronikova, S.

Publications and source records attributed to Baronikova, S..

2 recordsLinked to original sources

Benchmarking open access publication rates for the pharmaceutical industry and research-intensive academic institutions

BackgroundIn biomedical and health sciences, many articles are published open access (OA). OA publication rates continue to grow, especially for pharmaceutical research. Previous analyses of pharmaceutical OA publication rates were labor-intensive and not easily automated. We aimed to create a free, live, online dashboard comparing OA publication rates between pharmaceutical companies and academic institutions. MethodsUsing the Lens - an online platform aggregating full-text content and metadata for over 280 million scholarly works - we built a dashboard showing OA publication rates for medical research articles by authors from the top 40 pharmaceutical companies (pharma) and 40 research-intensive academic institutions (academia). The dashboard details OA rates by model, license and therapy area across three time frames: 12-24 months; 0-12 months; 0-10 years. We downloaded data from the dashboard between 24 July and 4 August 2023 and performed further analysis. ResultsOf the articles published 12-24 months before data extraction, 76.6% by pharma and 69.5% by academia were OA. The most common OA models were gold (pharma, 37%; academia, 41%) and hybrid (pharma, 22%; academia, 11%). Oncology had lower rates of OA articles than other therapy areas. In the 10 years before data extraction, growth in the OA publication rate was generally more rapid for pharmaceutical companies than for academic institutions, regardless of field (change in overall % OA 2013-2023: pharma, 3.1; academia, 1.6). ConclusionsThis dashboard provides novel and regularly updated evidence on the comparative OA publication practices of pharmaceutical companies and academic institutions. In our snapshot analysis, the OA publication rate was higher for pharmaceutical companies than for academic institutions and continues to increase. Notable differences were observed in approaches, in terms of licenses and OA models, which may reflect different institutional practices and circumstances. We encourage others to use this open resource for new research and to report their results.

scientific communication and education↗

Commitments by the biopharmaceutical industry to clinical trials transparency: the evolving environment

BackgroundSponsors of clinical trials have ethical obligations to register protocols, to report study results and to comply with applicable legal requirements.\n\nObjectiveTo evaluate public commitments to trial disclosure and rates of disclosure by members and non-members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and/or the Pharmaceutical Research and Manufacturers of America (PhRMA).\n\nStudy selectionWebsites of the top 50 biopharmaceutical companies by 2015 sales were searched for statements relating to trial data disclosure. Disclosure of trial results completed by biopharmaceutical industry and non-industry sponsors of at least 30 trials (2006-2015) was assessed using TrialsTracker.\n\nFindingsAmong the top 50 companies, 30 were EFPIA/PhRMA members and 20 were non-members, of which 26 and none, respectively, had a statement on their website committing to the disclosure of trials data. Of 29 377 trials in TrialsTracker, 9511 were industry-sponsored (69 companies) and 19 866 were non-industry-sponsored (254 institutions). The overall mean disclosure rate was 55%, with higher rates for industry (74%) than for non-industry sponsors (46%). Of the 30 companies within the top 50 with data in TrialsTracker, the mean disclosure rate was 76% (77% for EFPIA/PhRMA members [n = 25] versus 67% for non-members [n = 5]).\n\nConclusionsMost of the top 50 biopharmaceutical companies have publicly committed to the disclosure of trial data. Industry sponsors have responded to the ethical and legal demands of trial disclosure to a greater extent than non-industry sponsors, and now disclose three quarters of their trials.

scientific communication and education↗